Business
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics,
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy\nSOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of aficamten, an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM). Cohort 4 will enroll patients with non-obstructive hypertrophic cardiomyopathy. “Approximately one third of people with HCM have non-obstructive HCM, and while they do not have left ventricular outflow tract obstruction, they still have considerable functional limitations and symptom burden with few treatment options,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “By investigating the safety and tolerability of aficamten in patients with non-obstructive HCM in a fourth cohort of REDWOOD-HCM we believe we may be able to advance more expeditiously into a potential pivotal clinical trial in non-obstructive HCM thereafter.” REDWOOD-HCM: Cohort 4 REDWOOD-HCM is a Phase 2, multi-center, randomized, placebo-controlled, double-blind, dose finding clinical trial of aficamten in patients with HCM. The primary objective of the trial is to determine the safety and tolerability of aficamten. Cohorts 1 and 2 enrolled patients with symptomatic obstructive HCM taking background medications exclusive of disopyramide while Cohort 3 enrolled patients taking background medications including disopyramide. Cohort 4 will enroll, in an open label fashion, 30-40 patients with symptomatic non-obstructive HCM receiving background medical therapy. At screening, patients must have a left ventricular ejection fraction (LVEF) of ≥60%, an elevated NT-proBNP >300 pg/mL, and must not have resting or post-Valsalva LVOT gradients (","length":2503,"tagName":"div"}]